Clinical trials: Constipation Drug Induced
Constipation, Bowel Dysfunction
Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication
A multicenter study to evaluate the effectiveness and safety of multiple dosage regimens of an investigational drug for the treatment of constipation due to prescription pain medication in subjects with cancer pain.
- Trial name
- NCT00101998
- Testing
- alvimopan
- Where
- 162 sites in United States, Argentina and 24 more
- Volunteers
- 233 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Drug Induced Constipation
Study in Healthy Volunteers to Investigate the Effects of Diltiazem on the Pharmacokinetics of Naloxegol
Study in healthy volunteers to investigate the effects of Diltiazem on the Pharmacokinetics of naloxegol.
- Trial name
- NCT01594619
- Testing
- Naloxegol, Diltiazem XR
- Where
- United States
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Drug Induced Constipation
Study in Healthy Volunteers to Investigate the Effects of Quinidine on the Pharmacokinetics of NKTR-118
Study in healthy volunteers to investigate the effects of Quinidine on the Pharmacokinetics of NKTR-118
- Trial name
- NCT01533155
- Testing
- Nektar 118, Quinidine, Morphine
- Where
- United States
- Volunteers
- 214 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Drug Induced Constipation
Study in Healthy Volunteers to Investigate the Effects of Rifampin on the Pharmacokinetics of NKTR-118
Study in healthy volunteers to investigate the effects of Rifampin on the Pharmacokinetics of NKTR-118.
- Trial name
- NCT01533870
- Testing
- NKTR-118, Rifampin
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Opioid-Induced Constipation
Safety and Preliminary Efficacy of BGP345A in Constipation Due to Opioid-based Medications
The purpose of this study is to assess safety and preliminary efficacy of BGP345A in patients with constipation due to the use of opioid-based medications for the management of chronic non cancer pain.
- Trial name
- OIC1 (NCT05133076)
- Testing
- Lactobacillus gasseri BGP345A
- Where
- 4 sites in France
- Volunteers
- 14 people
- Sponsor
- BioGaia Pharma AB
Opioid Induced Constipation
Naloxegol Drug Utilization Post Authorisation Safety Study
This post-authorization observational safety study determines the characteristics of patients prescribed naloxegol at time of first prescription and treatment patterns of naloxegol in follow-up in the United Kingdom (UK), Norway…
- Trial name
- NCT02813148
- Testing
- Naloxegol
- Where
- 4 sites in Germany, Norway and 2 more
- Volunteers
- 17,254 people
- Sponsor
- Kyowa Kirin Pharmaceutical Development Ltd
Opioid-induced Constipation
Risk of Major Adverse Cardiovascular Events for Naldemedine & Other Medications for Opioid Induced Constipation
The research objective is to characterize the risk of a major adverse cardiovascular event (MACE) among new users of naldemedine versus new users of lubiprostone and new users of naloxegol as comparator opioid induced…
- Trial name
- NCT03720613
- Testing
- Naldemedine, Lubiprostone, Naloxegol
- Where
- United States
- Volunteers
- 34,532 people
- Sponsor
- BioDelivery Sciences International